Compare ALAR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALAR | CGTX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7M | 110.8M |
| IPO Year | 2018 | 2021 |
| Metric | ALAR | CGTX |
|---|---|---|
| Price | $7.40 | $1.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $14.00 | $3.33 |
| AVG Volume (30 Days) | 36.1K | ★ 943.2K |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.51 | N/A |
| Revenue Next Year | $33.43 | N/A |
| P/E Ratio | $44.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $0.22 |
| 52 Week High | $18.00 | $3.83 |
| Indicator | ALAR | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.16 | 43.48 |
| Support Level | $7.27 | $1.01 |
| Resistance Level | $7.82 | $1.19 |
| Average True Range (ATR) | 0.61 | 0.09 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 53.30 | 5.45 |
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).